Intervention not reported
Complete relief of AMS symptoms · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Reduction in symptom score severity at 12 hours (Clinical score: ranged from 0 to 11 (worse)) Intervention: Simulated descent of 193 millibars versus 20 millibars · people suffering from high altitude illness
1 finding from 1 review
Intervention not reported
Adverse effects during treatment Intervention: Hyperbaric chamber/ 160 millibars versus supplementary oxygen · people suffering from high altitude illness
1 finding from 1 review
Intervention not reported
All‐cause mortality · people suffering from high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Complete relief of AMS symptoms (12 to 16 hours after treatment) Scale used: Acute Mountain Sickness score (ranged from 0 to 9 (worse)) · people suffering from high altitude illness
1 finding from 1 review
Intervention not reported
Reduction in symptom score severity Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement: Self‐administered AMS questionnaires (ranged from 0 to 90 (worse)), AMS Symptom Questionnaire (ranged from 0 to 22 (wors... · people suffering from high altitude illness
The intervention showed no clear difference in reduction in symptom score severity Time of measurement: 1 to 48… (low certainty).
1 finding from 1 review
Intervention not reported
Adverse effects Time of measurement: 1 to 48 hours after treatment, end of treatment Scale of measurement:not stated · people suffering from high altitude illness
1 finding from 1 review
Mortality, near term corrected age or discharge · preterm infants
Lower showed no clear difference in mortality, near term corrected age or discharge compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Neurodevelopmental disability · preterm infants
Lower showed no clear difference in neurodevelopmental disability compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Intubation in the delivery room · preterm infants
Lower showed no clear difference in intubation in the delivery room compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe (defined as stage 3 or greater) retinopathy of prematurity ‐ not reported · preterm infants
Lower showed no clear difference in severe retinopathy of prematurity (≥ stage 3) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Severe intraventricular haemorrhage · preterm infants
Lower showed no clear difference in severe intraventricular haemorrhage (grade 3 or 4) compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Necrotising enterocolitis · preterm infants
Lower showed no clear difference in necrotising enterocolitis compared with higher oxygen concentrations titrated to target oxygen saturations… (low certainty).
1 finding from 1 review
Chronic lung disease · preterm infants
It is very uncertain whether lower changes chronic lung disease (36 weeks' corrected age) compared with higher oxygen concentrations titrated to target oxygen saturations… (very low certainty).
1 finding from 1 review
Risk of acute mountain sickness · participants at risk of high altitude illness
Sumatriptan may leads to lower risk of acute mountain sickness compared with placebo (low certainty).
1 finding from 1 review
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of acute mountain sickness · participants at risk of high altitude illness
Acetazolamide may leads to lower risk of acute mountain sickness compared with spironolactone (low certainty).
1 finding from 1 review
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of adverse events ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Risk of acute mountain sickness · participants at risk of high altitude illness
Magnesium citrate showed no clear difference in risk of acute mountain sickness compared with placebo (low certainty).
1 finding from 1 review